A Medicare GLP-1 bridge program marks 2026, while multiagonists like CagriSema are poised to lead the next wave of obesity therapy.
Anne M. Komé, PharmD, CPP, BCACP, CDCES
Advertisement
Articles by Anne M. Komé, PharmD, CPP, BCACP, CDCES
Advertisement
Latest Updated Articles
Patient-First Language Cuts Weight Stigma in CareAugust 31st 2026
Komé on the Next Wave of Obesity TherapiesSeptember 11th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5